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Key contributions to protein structure and stability are pro-
videdbyweakly polar interactions,which arise fromasymmetric
electronic distributions within amino acids and peptide bonds.
Of particular interest are aromatic side chainswhose directional
-systems commonly stabilize protein interiors and interfaces.
Here, we consider aromatic–aromatic interactions within a
model protein assembly: the dimer interface of insulin. Semi-
classical simulations of aromatic–aromatic interactions at this
interface suggested that substitution of residue TyrB26 by Trp
would preserve native structure while enhancing dimerization
(and hence hexamer stability). The crystal structure of a
[TrpB26]insulin analog (determined as a T3Rf3 zinc hexamer at a
resolution of 2.25 Å) was observed to be essentially identical to
that of WT insulin. Remarkably and yet in general accordance
with theoretical expectations, spectroscopic studies demon-
strated a 150-fold increase in the in vitro lifetime of the variant
hexamer, a critical pharmacokinetic parameter influencing
design of long-acting formulations. Functional studies in dia-
betic rats indeed revealed prolonged action following subcuta-
neous injection. The potency of the TrpB26-modified analogwas
equal to or greater than an unmodified control. Thus, exploiting
a general quantum-chemical feature of protein structure and
stability, our results exemplify a mechanism-based approach to
the optimization of a therapeutic protein assembly.
Weakly polar interactions are ubiquitous among protein
structures (1). Among such interactions, the relative packing of
aromatic rings is of particular interest in relation to the organi-
zation of protein cores and subunit interfaces (2). Aromatic–
aromatic interactions are governed by quantum-chemical
properties, which underlie dispersion forces and give rise to
asymmetric distribution of partial charges. Whereas aromatic
stacking is prominent in nucleic acid structures, pairs of aro-
matic side chains in proteins more often exhibit edge-to-face
(ETF)4 contacts (3). Can such contacts be exploited in thera-
peutic protein engineering? Here, we have analyzed aromatic–
aromatic interactions in the insulin hexamer (4) as a basis for
designing improved long-acting (basal) analogs. This class of
analogs is central to the treatment of Type 1 and Type 2 diabe-
tes mellitus (5).
Classical crystal structures of insulin hexamers (6, 7) imme-
diately suggested a pathway of assembly (4). Pertinent to the
mechanism of storage in the secretory granules of pancreatic
-cells (8), such assembly is also of pharmacologic importance
(9). Insulin assembly both protects the hormone from degrada-
tion in pharmaceutical formulations and modulates its phar-
macokinetic properties (10). Indeed, the first use of insulin ana-
logs in diabetes therapy reflected efforts to destabilize the
insulin hexamer and thereby accelerate absorption of mono-
mers and dimers from the subcutaneous (SQ) depot (summa-
rized in Fig. S1 (11, 12)). Because it is more straightforward to
introduce unfavorable substitutions than favorable ones, such
engineering (corresponding to rapid-acting analogs) was more
successful than complementary efforts to enhance the thermo-
dynamic (and kinetic) stability of the insulin hexamer (13).
There are presently three rapid-acting insulin analogs in clini-
cal use (14), but no basal products designed on the basis of
enhanced hexamer assembly despite extensive efforts (15).
These difficulties were circumvented by alternative mecha-
nisms of protracted action (acylation and pH-dependent SQ
precipitation (14); Fig. S2).
The dimer interface of insulin (repeated three times in the
hexamer) contains a cluster of eight conserved aromatic rings
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(TyrB16, PheB24, PheB25, TyrB26, and their dimer-related mates
in subunit D; Fig. 1,A–C). Of these, successive ETF contacts are
formed by B16–D26, B24–B26, B24–D24, and B26–D16; the
B25 side chain is peripheral to this network. Whereas variation
at these sites is in general constrained by the structure of the
hormone–receptor interface (16, 17), our attention focused on
the B26 side chain because of its functional tolerance to diverse
substitutions (18) and because of its partial exposure in the
monomer, dimer, and hexamer (4) (Fig. 1,C andD).We sought
to investigate whether variant B16–D26 and B26–D16 ETF
contacts across the dimer interface might in principle modu-
late, in either direction, the strength of these interactions. We
hypothesized that enhanced ETF contacts at this interface
might provide the long-sought approach to stabilize the insulin
hexamer and so improve the pharmacokinetc properties of
basal formulations.
The present study had three parts. The first employed local
modeling, using the standard CHARMM empirical energy
function, to probe possible effects of a TyrB263 Trp substitu-
tion on aromatic–aromatic interactions within the wildtype
(WT) aromatic cluster. These molecular mechanics (MM) cal-
culations suggested that substitution of TyrB26 by Trp could
enhance dimer-related ETF contacts and yet otherwise pre-
serve a native-like interface. We next prepared this analog to
examine whether this substitution might indeed stabilize the
insulin hexamer and retard its disassembly while preserving the
biological activity of the monomeric hormone. The crystal
structure of a [TrpB26]insulin analog (as a zinc–insulin hex-
amer) was essentially identical to that ofWT insulin. Finally, we
undertook studies in diabetic rats to obtain proof of principle
that this approach could extend the duration of insulin action
on SQ injection.
Figure 1. Structural overview of insulin. A, sequence of insulin with disulfide bridges in black. TyrB26 is highlighted in black; the present TyrB263 Trp
substitution is orange; and modifications in pI-shifted clinical analog glargine in purple. Our semisynthetic pI-shifted analog contained Orn (green)
instead of Lys or Arg. B, structure of an insulin monomer; the A chain is shown in black and B chain in green. TyrB26 is red, whereas PheB24 and TyrB16 are
blue (PDB code 4INS). C, structure of zinc-coordinated insulin hexamer (T6 state), a trimer of dimers; Tyr
B26, PheB24, and TyrB16 are color-coded as in B. D,
stereo view showing TyrB26 (sticks) in a cavity within insulin dimer (extracted from T3R
f
3 hexamer, PDB code 1TRZ). E, corresponding stick model with
residues labeled.
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Toour knowledge, our results represent the first exploitation
of aromatic–aromatic interactions to enhance the physical and
biological properties of a therapeutic protein. Because standard
MM calculations employ a simplified model of aromatic sys-
tems (i.e. approximating their quantum-mechanical (QM)
properties via partial atomic charges (19, 20)), ab initio QM
simulations of the aromatic cluster and their incorporation in
QM/MM simulations (21) promise to establish a rigorous
foundation for therapeutic protein design, including further opti-
mization through incorporation of modified or nonstandard
amino acids (22–24). The present results suggest that insulin’s
conserved aromatic cluster can provide a natural laboratory for
such foundational analysis and its therapeutic translation.
Results
Molecularmechanics calculations suggested that augmented
aromatic–aromatic interactions are possible at the TrpB26
dimer interface
MM simulations were employed to estimate the strength of
aromatic–aromatic interactions of TrpB26 at the insulin dimer
interface in relationship to those of the native Tyr. These cal-
culations employed the CHARMM empirical energy function
in which aromatic rings contain partial atomic charges, param-
etrized to mimic the electrostatic properties of the -system
(19, 20).Workingmodels of the variant dimer were obtained by
local energy minimization (see “Experimental procedures”).
Energies of interaction between the eight aromatic residues
at the insulin–dimer interface (TyrB16, PheB24, PheB25, TyrB26,
and their symmetry-related mates) were calculated using local
models in which TrpB26 was substituted withinWTT2, R2, and
TRf reference dimers (extracted from PDB structures 4INS,
1ZNJ, and 1TRZ) (25). The total interaction energy between
B26 and the other aromatic residues at the TrpB26 interface,
which was calculated using the full CHARMMpotential energy
function, was augmented by 2.0 and 0.8 kcal/mol relative to the
minimized WT interface in the context of R2 and TRf struc-
tures, respectively, and diminished by 1.5 kcal/mol in the con-
text of the T2 structure. Results are summarized in Table S1.
A minimal model was utilized to further evaluate the poten-
tial impact of a TrpB26 substitution on aromatic–aromatic
interactions at the dimer interface. To this end, a structural
model of the dimer interface (extracted from a T6 insulin hex-
amer; PDB code 4INS) was first built containing residue B26
(TyrB26 or TrpB26) and its nearest aromatic neighbors (PheB24,
PheD24, or TyrD16). Simulations predicted the orientation of the
B26 ring corresponding to free-energy minima of electrostatic
interactions between the aromatic residues (the partial-charge
parametrization of aromatic residues in CHARMM is shown in
Fig. S3) (23). When substituted at position B26, Trp displayed
improved electrostatic interactions with its three aromatic neigh-
bors (relative to theWTTyr) over a broad range of conformations
(Fig. 2). This trend extended to conformations that are sterically
permitted in the context of theWT insulin hexamer.
TrpB26 analog exhibitedmarkedly decreased hexamer
dissociation rate
The effect of theTrpB26 substitution on the lifetime of insulin
hexamers under formulation conditions was assessed in the
context of [OrnB29]insulin, a structural equivalent of WT insu-
lin that is amenable to production by trypsin-catalyzed semi-
synthesis (26). The lifetime of Co2-substituted, phenol-stabi-
lized (R6) hexamers of [TrpB26,OrnB29]insulin was assessed at
equilibrium in relationship to native [TyrB26,OrnB29]insulin.
Optical absorbance spectra of these analogs (characteristic of
Co2with tetrahedral coordination)were similar toWT (Fig. 3,
A and B). Assessment of R6 dissociation rates (summarized in
Table 1) revealed a 150-fold increase in hexamer half-life of the
TrpB26 analog relative to its parent [OrnB29]insulin (Fig. 3, C
and D). This increase is remarkable given that the difference
between the half-lives of a rapidly dissociating analog in clinical
use (lispro)5 (27–29) and WT is2-fold (Table 1).
TrpB26 imposed kinetic barriers to the dissociation of hexamers
intomonomers
R6 dissociation kinetics were further examined by size exclu-
sion chromatography (SEC). The TrpB26 analog (formulated in
the presence of phenol and zinc ions) was injected onto an SEC
column using a zinc- and phenol-free mobile phase. Subse-
quent dissociation of the R6 hexamers was monitored in the
chromatograms (Fig. 4A, Table 1). Absence of a void volume
signal (V0) indicated that none of the proteins formed large
nonspecific aggregates. Whereas WT and [OrnB29]insulin
eluted as a broad peak representing an association state inter-
mediate betweenmonomer and dimer (9.7 and 8.2 kDa, respec-
tively) and insulin lispro eluted essentially as a monomer (5.1
kDa), [TrpB26,OrnB29]insulin eluted in two distinct peaks. The
larger peak corresponded to a trimeric or tetrameric associa-
tion state (molecular mass 28 kDa), and the smaller corre-
sponded to amonomeric state (4 kDa; Fig. 4,A andB; see Fig. S4
5 Insulin lispro, containing substitutions ProB28 3 Lys and LysB29 3 Pro,
exhibited an attenuated574-nmband (69); this is associatedwith agreater
proportion of spectroscopically attenuated T3R
f
3 hexamer and invisible T6
hexamer (Fig. 3B).
Figure 2. Molecular simulations of aromatic interactions in the insulin
dimer.A, aromatic–aromatic interactionsacross insulin’sdimer interface involve
PheB24, TyrB16, PheD24 (sticks) and either TyrD26 (left) or TrpD26 (right). Residues
wereextracted fromT6 structure4INS.B,contourmapsdepictingempirical inter-
action energies between B26 (Tyr on left and Trp on right) at varying 1 and 2
angles and the other three residues shown in A. The orientation of TyrB26 or
TrpB26 in theWTor variant crystal structure is indicatedbyagreen “x”; orientation
of TyrB26 or TrpB26 in the localmodel is indicated by a green asterisk.
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for reference chromatograms of the monomer and hexamer).
These findings suggest that oligomers intermediate between
hexamer and dimer may delay dissociation of the TrpB26 ana-
log; in particular, the absence of broad elution tails implies that
TrpB26 imposes significant barriers to rapid dissociation.
TrpB26 analog retained native biological activity
The in vitro affinity of the TrpB26 analog for the lectin-puri-
fied insulin receptor (IR; isoform B holoreceptor) was deter-
mined to be 0.14(0.02) nM, 50% that of [OrnB29]insulin
(0.07(0.02) nM) and WT insulin (0.08(0.03) nM) (Fig. 5A).
The potencies of these analogs, evaluated by intravenous (i.v.)
injection in diabetic rats, were nonetheless, indistinguishable
fromWT insulin (Fig. 5B).
TrpB26 analog displayed a zinc-dependent delay in onset of
biological activity
Hexamer assembly delays absorption of insulin from its SQ-
injection site (11, 12). To assess the onset and duration of
[TrpB26,OrnB29]insulin relative to [OrnB29]insulin, the pharma-
codynamics (PD) profile of these proteins (made 0.15 mg/ml,
corresponding to a monomer concentration of 27 M and a
putative hexamer concentration of 4.5 M) were evaluated as
zinc-free solutions or as pre-assembled phenol-stabilized R6
hexamers in the presence of excess zinc ions (0.30mMZnCl2; 70
zinc ions per hexamer). A zinc-dependent delay in onset of
activitywas observed on SQ injection of [TrpB26,OrnB29]insulin
but not on injection of [OrnB29]insulin or WT insulin (Fig. 5C;
see Fig. S5 for WT results). Whereas the latter PD profiles
exhibited a nadir at about 120 min irrespective of the zinc
ion concentration, the PD profile of [TrpB26,OrnB29]insulin
occurred at (i) 120 min in the absence of zinc ions and (ii) 150
min in the presence of 0.30 mM zinc ions with corresponding
delays in the rate of fall over the first 30min (Fig. 5D). Together
with the above in vitro results, these findings suggest that the
prolonged lifetime of the TrpB26 R6 hexamer (as inferred from
the above kinetic studies of the Co2-substituted hexamer) are
responsible for the inferred zinc-dependent delay in SQ
absorption.
TrpB26 protracted the PD profile of amodel pI-shifted analog
Insulin analogs with isoelectric points (pI) shifted to neutral
pH generally exhibit prolonged activity due to precipitation in
the SQ depot (30). To determine whether TrpB26 might further
prolong the activity of such analogs, this substitution was in-
troduced into a [GlyA21,OrnB29,OrnB31,OrnB32]insulin. This
“glargine-like” framework was designed to recapitulate the pI
shift of glargine with greater ease of semisynthesis.6 The pro-
teins (formulated at 0.6 mM with 0.3 mM ZnCl2, corresponding
to 3 zinc ions per hexamer) were each injected SQ in diabetic
rats.
The pI-shifted parent analog displayed peak activity at about
120 min with blood glucose levels returning to baseline after
about 360 min. By contrast, its TrpB26 derivative displayed a
prolonged PD profile: peak activity occurred 180min with slow
return to baseline at 800 min (Fig. 5E; see Fig. S6 for i.v.
potency). Such amarked delay in peak activitywas not observed
in the parent glargine-like analog or the TrpB26 derivative when
administered in the absence of zinc (Fig. S7). These results sug-
gest that TrpB26 may favorably be incorporated into current
basal analogs as a complementary mechanism of prolonged SQ
absorption.
Crystal structure of TrpB26 analog demonstrated native-like
dimer interface
The crystal structure of [TrpB26,OrnB29]insulin was deter-
mined as a zinc-coordinated hexamer in the presence of phenol
to a resolution of 2.25 Å. Diffraction and refinement statistics
are provided in Table S2. The asymmetric unit constituted a
“TRf” dimer7 (31, 32). The overall structures of the T and Rf
protomers were essentially identical to those of WT insulin
(Fig. S8) with respective r.m.s. deviations of 1.11  0.30 and
6 This analog simulated pI-shifted insulin glargine, which contains two
additional arginine residues at the C-terminal B chain (B31 and B32) and
a substitution of AsnA21 by Gly (see Fig. 1A) (29, 69). Use of Orn permit-
ted semisynthesis.
7 One protomer in the (dimeric) asymmetric unit adopted the classical “T”
conformation (Fig. 1B); the other adopted in the frayed R state (31, 32) in
which residues B3–B8 extend the B-chain -helix.
Figure 3. Hexamer dissociation of TrpB26 analog. A, tetrahedral Zn2-co-
ordination site in R6 insulin hexamer (ball-and-stick model): three His
B10 side
chains and one chloride ion. B, absorbance spectra of d–d bands in corre-
sponding Co2 complex; the color code is indicated. C, hexamer dissociation
curves as monitored at 574 nm after addition of excess EDTA; the color code
is as in B. The lifetime of the [TrpB26,OrnB29]insulin hexamer was markedly
prolonged (asterisk).D,dissociationof TrpB26,OrnB29 hexamer from0 to8000 s
in relationship to that of parent [OrnB29]insulin (black arrow). Half-lives are
given in Table 1.
Table 1
Self-association properties of insulin analogs
Analog
t1⁄2 hexamer
dissociation
Calculated molecular
mass by SECa
min S.D. kDa
Wildtype 7.7 ( 1.3) 9.7
Lisprob 4.6 ( 0.3) 5.1
OrnB29c 8.2 ( 0.8) 8.2
TrpB26, OrnB29 1.2 ( 0.3) 103 28.0, 4.0
a Proteins were made 0.6 mM in a buffer containing ZnCl2 at a ratio of 2 zinc ions
per insulin hexamer and applied to SEC column as described under “Experi-
mental procedures.” Masses were calculated from the plot in Fig. 4B.
b “Lispro” describes insulin analogs containing ProB283Lys and LysB293Pro
substitutions. These substitutions impair dimerization (28, 29).
c Use of Orn simplified trypsin-catalyzed semisynthesis (33).
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1.36 0.30. Additional r.m.s. deviations are given in Tables S3
and S4. Side chain packing near the B26 position was largely
unperturbed. In both protomers the TrpB26 indole group was
oriented with its six-member ring packing against conserved
core residues IleA2, ValA3, and ValB12 (Fig. 6); the indole NH
group is exposed to solvent in theTRdimer andT3Rf3 hexamer.
TheTrpB26 side chain in both R andT protomers also displayed
dihedral angles within the range of the native Tyr inWT crystal
structures (Tables S5 and S6, respectively) with a slight devia-
tion in the positioning of the peptide backbone to accommo-
date the larger indole side chain.
Spectroscopic probes revealed native-like structure and
thermodynamic stability of TrpB26 analogs in solution
The native-like crystal structure of [TrpB26,OrnB29]insulin is
in accordance with its unperturbed circular dichroism (CD)
spectrum and thermodynamic stability under monomeric con-
ditions (Fig. 7A). Free energies of unfolding (Gu 3.3  0.1)
kcal/mol at 25 °C as inferred from two-statemodeling of chem-
ical denaturation (33)) were indistinguishable due to small and
compensating changes in transition midpoint and slope (m
value) (33, 34) (Fig. 7B, Table 2). Further evidence that the crys-
tal structure extends to the monomer in solution was provided
by 2D 1H NMR studies of TrpB26 substituted within an engi-
neered insulinmonomer (lispro (35)).Whereas the spectrumof
lispro (at pD 7.6 and 37 °C) exhibits sharp resonances for each
aromatic spin system (Fig. 8A), as expected for a monomeric
analog (35), the spectrum of its TrpB26 derivative exhibits
broadening of resonances at the dimer interface (B16, B24–
B26). The latter spin systems can be observed on TOCSY spec-
trum (Fig. 8C) but not in the corresponding DQF-COSY spec-
trum due to antiphase cancellation. Like the aromatic ring
TyrB26 in spectra of insulin lispro (Fig. 8, A and B), the indole
ring exhibited regiospecific nonlocal nuclear Overhauser
enhancements (NOEs) from its six-member moiety to the
methyl resonances of ValB12 and IleA2 (Fig. 8, B–D).
The pattern of secondary shifts in the variant is similar to that
in the parent monomer. In particular, the aromatic 1H NMR
resonances of TrpB26 (red cross-peaks in Fig. 8C) exhibit upfield
features (relative to Trp in the isolated B23–B30 octapeptide;
dashed lines) similar to those of TyrB26 in the parent spectrum
(purple cross-peaks in Fig. 8A versus dotted lines) (36). Dilution
of the TrpB26 sample partially mitigated resonance broadening
but preserved these trends in dispersion. Indole-specific NOEs
indicated that the side chain assumes one predominant
and asymmetric conformation within a native-like crevice
between A- and B-chain -helices (Table S7). Because
TyrB26 undergoes rapid ring rotation about the C–C bond
axis (“ring flips”), analogous side chain-specific NOEs
(inferred in prior studies from molecular modeling) cannot
be observed directly (Table S8).
Figure 4. Size exclusion chromatography of TrpB26 hexamer. A, SEC chromatogram of insulin analogs in the presence of zinc and phenol. The void volume
(V0, black arrow) was defined by thyroglobulin (molecular mass 669 kDa). B, plot of log(molecular weight) versus elution ratio (Ve/V0) of molecular weight
standards. Linear relationship between log[MW] to elution ratio (Ve/V0) is indicated by the red linewith coefficient of determination (R
2) 0.996 and parameters
log[molecular weight]	
1.71 (Ve/V0) 6.7012. Elution times of molecular weight standards are indicated by blue squares (labeled by molecular weight).
Identity ofmolecularmass standards is as follows: 66 kDa, BSA; 45 kDa ovalbumin; 20 kDa, carbonic anhydrase, 17 kDa, myosin light chain; 12.4; cytochrome c,
6.5 IGF-I. CalculatedMr are given in Table 1.
Figure 5. Pharmacology of TrpB26 analog. A, receptor-binding affinities
(isoform B). The affinity of [TrpB26,OrnB29]insulin was reduced by 2-fold rela-
tive to [OrnB29]insulin (respective Kd estimates 0.14 (0.03) and 0.07 (0.02)
nM). Color code is indicated in the inset. B, time course of [blood glucose]
following i.v. injection in rats (n	 15); color code as in A. C, time course of
[blood glucose] following SQ injection in the absence or presence of 0.3
mM ZnCl2 (n 	 18). D, histogram summarizing the rate of fall of [blood
glucose] over the first 30 min in C, black bars indicate S.D. E, time course of
[blood glucose] following SQ injection of pI-shifted analogs: [GlyA21,
OrnB29,OrnB31,Orn32]insulin, and its TrpB26 derivative (n 	 6; color code in
panel).
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MMcalculations suggested improved aromatic–aromatic
interactions within the variant crystal structure
The contribution of aromatic–aromatic interactions involv-
ing TrpB26 to the stability of the variant dimer interface of the
T3Rf hexamer was evaluated through calculation of nonbonded
interaction energies among aromatic residues B16, B24, B25,
and B26 in the TRf dimer. These calculations, which employed
the variant crystal structure, were in overall accordance with
expectations based on our initial local MM-based modeling
(above). In particular, based on aromatic–aromatic interac-
tions alone, the TrpB26,OrnB29 dimer displayed an increase in
interaction energy of 1.4 kcal/mol relative toWTTRf reference
structure PDB 1TRZ; the results of these calculations are given
in Table S9, a and b. Although the standard CHARMM empir-
ical energy function, when applied to analyze either crystallo-
graphic and MM-minimized models of [TrpB26]insulin, sug-
gested that the electrostatic properties of the Trp side chain
were the primary contributors to the increased stability of the
dimer, this physical interpretationmay reflect the limitations of
the partial-charge representation (23, 37). Indeed, preliminary
ab initioQMsimulations of aminimalmodel (consisting of two
aromatic rings in vacuo) predicted that enhanced Van der
Waals interactions may also make a significant contribution
(Fig. S9) (see “Discussion”).
Discussion
The physical origins of protein stability and recognition
define a foundational problem in biochemistry (38)with central
application to molecular pharmacology (39). The zinc–insulin
hexamer provides a favorable system for structure-based design
due to its long history of crystallographic investigation (40).
Indeed, the hexamer’s rigidity, as interrogated by NMR spec-
troscopy (41), renders the overall structure robust to diverse
amino acid substitutions (42, 43), even those that destabilize the
dimer interface8 (32, 44). This rigid framework has often
enabled analysis of discrete interactions without complications
due to the long-range transmission of conformational change
(31, 32).
Our studies, stimulated by the seminal recognition of
aromatic–aromatic interactions by Burley and Petsko (2) more
than 30 years ago, focused on the classical dimer interface, a
basic building block of the hexamer (32). Long appreciated as “a
thing of beauty” (4, 45), this interface contains eight aromatic
residues, six of which engaged in a successive set of aromatic–
aromatic interactions. Quantum-chemical simulations of
model systems have suggested that nearest-neighbor interac-
tions predominate even in the presence of multiple rings (46).
Pairwise dissection of insulin’s dimer interface has highlighted
8 An exception is provided by a substitution at the primary zinc-binding site
(His
B10
3 Asp), which converts the hexamer into a novel dodecamer with
zinc-coordination mediated by HisB5 (26). The structure of each protomer
is native-like.
Figure 6. Crystal structure of [TrpB26,OrnB29]insulin. A, electron density of TrpB26 in T-state protomer showing the surrounding density in TRf asymmetric
unit (contour level 2.0 Å). B, stickmodel corresponding tomap in A; TrpB26 is orange. C, surfaces of residues surrounding TrpB26 (sticks) as indicated above.D–F,
corresponding map and models of TrpB26 in the R state protomer.
Figure 7. Thermodynamic stability of [TrpB26,OrnB29]insulin. A, CD spec-
tra of [TrpB26,OrnB29]insulin, [OrnB29]insulin, and WT insulin. B, guanidine
denaturation assays of insulin analogs monitored by ellipticity at 222 nm;
color code as in A. Stabilities are given in Table 2.
Table 2
Thermodynamic stabilities of insulin analogs
Analog Gua Cmid mb
kcal mol
1 M kcal mol
1 M
1
Wildtype 3.4 0.1c 5.0 0.1 0.68 0.02
OrnB29 3.3 0.1 4.9 0.1 0.67 0.01
TrpB26,OrnB29 3.3 0.1 5.1 0.2 0.64 0.03
a Parameters were inferred from CD-detected guanidine denaturation data by ap-
plication of a two-state model; uncertainties represent fitting errors for a given
data set.
b Them-value (slope (G)/(M)) correlates with surface area exposed on
denaturation.
c Analysis of replicates of [TrpB26,OrnB29]insulin, parent [OrnB29]insulin, and WT
samples indicated that experimental standard errors were equal to or less than
the above fitting errors:0.1 kcal mol
1 (Gu),0.1 M (Cmid), and0.01 kcal
mol
1 M 
1 (m).
Stabilization of insulin hexamer
10900 J. Biol. Chem. (2018) 293(28) 10895–10910
the potential opportunity to enhance its stability through sub-
stitution of TyrB26 by Trp. Whereas our crystallographic anal-
ysis verified that this substitution preserves native architecture,
a [TrpB26]insulin analog exhibited a dramatic increase in hex-
amer lifetime in vitro. Results of animal testing demonstrated
native intrinsic potency (i.e. on i.v. bolus injection) but with
prolonged activity on SQ injection, presumably due to delayed
dissociation of the variant zinc hexamers in the SQ depot.
Protein engineering of insulin analogs is constrained by the
complexity of insulin’s “conformational lifecycle”: from oxida-
tive folding intermediates and self-assembly in the pancreatic
-cell (8) to adoption of an active, “open” conformation on
receptor binding (Fig. 9, A and B) (16). Specific residues may
play distinct roles at each stage. In particular, because interfaces
within the insulin hexamer overlap the hormone’s receptor-
binding surface, essentially invariant among vertebrates (47),
modifications often impair activity (13). A given WT residue
may represent a compromise among competing structural
tasks. A recent survey of 18 substitutions at position B26
demonstrated that Tyr is suboptimal with respect to
IR-binding affinity but enhances self-assembly relative to
more active alternatives (Ala, Ser, or Glu) (18). The latter
side chains destabilize the “closed” dimer interface but are
favorable at the solvated B26-related edge of the open
hormone–receptor interface (Fig. 9C).
Protective self-assembly is of key pharmacologic importance
Insulin self-assembly protects the hormone from degrada-
tion and toxic misfolding in pancreatic -cells9 (8, 48) and in
pharmaceutical formulations (49). Because the zinc-insulin
hexamer exhibits delayed SQ absorption relative to monomers
and dimers, mutational destabilization of the hexamer (10, 12)
led to development of rapid-acting insulin analogs (14). Efforts
to stabilize the insulin hexamer, as a converse strategy to obtain
protracted action, were less successful (13). Current long-act-
ing insulin analogs rely instead on higher-order self-association
of hexamers within the SQ depot (30) and binding acylated
monomer to albumin as a circulating depot (highlighted in Fig.
S2) (50, 51).
The problem of how to improve a protein interface is in gen-
eral more subtle than its opposite, for destabilizing substitu-
tions abound at conserved interfaces, whereas stabilizing
substitutions can be rare (13). Structure-based candidate
substitutions may encounter entropy–enthalpy compensation
(EEC) (52, 53) or cause unintended biological perturbations
(54). The challenge posed by insulin is magnified by the struc-
9 An experiment of nature provided in vivo evidence for the relationship
between zinc coordination andprotection from toxic insulinmisfolding: in
the rodent species Octogon degus, substitution of HisB10 by Asn is associ-
ated with senile amyloidosis of the islets due to insulin fibrillation (70),
resulting in DM (48).
Figure 8. Homonuclear 2D NMR of a TrpB26 analog. 2D NMR studies of insulin analogs indicate similar TyrB26- and TrpB26 environments. A and B, spectra of
parent monomer insulin lispro ([LysB28,ProB29]insulin): A, aromatic region of TOCSY spectrumwith TyrB26 cross-peaks (magenta) shown relative to the Tyr spin
system in freeoctapeptideGFFYTKPT (dotted lines); andB, regionofNOESY spectrumshowingcontacts betweenaromatic protons (vertical axis,2) andmethyl
groups (horizontal axis,1). C andD, spectra of Trp
B26 analog of insulin lispro: C, aromatic TOCSY spectrumhighlighting TrpB26 cross-peaks (red) relative to the
Trp spin system in free octapeptide GFFWTKPT (dashed lines) and D, region of NOESY spectrum corresponding to B. B26-related NOEs are shown in red.
Cross-peak assignments: (a)-CH3 Val
A3, (b)-CH3 Val
B12, (c)-CH2,-CH3 Ile
A2, (d) 	-CH3 Leu
B15, (e)-CH3 Val
A3, (f)-CH3 Val
B12, (g)-CH2,-CH3 Ile
A2, (h) 	-CH3
IleA2, and (i) 	-CH3 Leu
B15. TOCSY mixing times in spectra A and Cwere 55 ms; NOESY mixing times in B and Dwere 150 ms.
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tural elegance of its self-assembly (as emphasized by Hodgkin
and colleagues (55) in a classic review). Diverse structure-based
strategies were previously undertaken with only limited suc-
cess. Alternate strategies previously used to create basal insulin
analogs are depicted in Fig. S2 and summarized in Table S10.
One approach focused on the general nonpolar character of the
dimer interface: additional hydrophobic substitutions were
introduced in an effort to enhance this feature (56). Such
designs were not successful and also impaired biological activ-
ity, although analogs were identified whose sparing solubility
slowed SQ absorption (56). A second approach exploited the
classical TR transition among insulin hexamers (57). At the
pivot point of this allosteric transition (Fig. S10), an invariant
glycine (GlyB8)was substituted by Ser in an effort to stabilize the
more stable R state hexamer (58). This analog was unstable as a
monomer (54) and exhibited reduced activity (58). Yet another
approach sought to stabilize the hexamer by relieving electro-
static repulsion created by the internal clustering of six acidic
side chains (GluB13): their isosteric substitution by Gln indeed
promoted assembly of zinc-free hexamers but impaired biolog-
ical activity (59). Overlap between the self-assembly surfaces of
insulin and its receptor-binding surfaces thus compounded the
optimization problem.
The present study revisited the architecture of the insulin
hexamer in light of recent insights into the hormone’s receptor-
binding surface (18). Prominent roles are played by a quartet of
aromatic residues in the C-terminal B-chain -strand: TyrB16,
PheB24, PheB25, and TyrB26 (33). These four residues, and the
clustering of eight dimer-related side chains, have long been the
focus of structure-activity relationships (60). Photoactivatable
aromatic probes (para-azido-Phe) at any of these sites exhib-
ited efficient cross-linking to the IR (61, 62). The co-crystal
structure of an insulin monomer bound to a fragment of the IR
ectodomain (the IR model) revealed distinct binding sites at
the surface of the L1 domain of the IR -subunit (B16, B24, and
B26) or its CT element (B24 and B25). PheB24 packs within a
nonpolar pocket near aromatic residues in L1 (residues Leu37
and Phe39) and CT (residue Phe714); one wall of this pocket is
defined by the aliphatic side chains of LeuB15, CysA20, and
CysB19 as in free insulin (16). This environment differs in detail
from those in the insulin dimer but exhibits analogous general
features. Although aromaticity is not required to fill the B24-
binding pocket (33), its specific size and shape constrain poten-
tial substitutions. TyrB16 lies at the periphery of L1 (near Phe39
and Lys40). Its substitution by Ala or other aromatic residues
preserves activity (63). PheB25 occupies a cleft between CT
Figure9. Binding surfaceof TyrB26 onan IR fragment.A,model ofWT insulin (in classical T-state) overlaid on the structure of insulin bound to an IR fragment
(PDB entry 4OGA). The L1 domain and part of the CR domain are shown in powder blue, whereas CT is shown in purple. PheB24 and TyrB26 are, respectively,
shown as gray and red sticks. The B-chain of IR-bound insulin is shown in dark gray (B6–B19) or black (B20–B27); the green tube indicates a classical location
withinoverlayof residuesB20–B30 (greenarrow), therebyhighlighting the steric clashofB26–B30withCT. Insertionof the insulinB20–B27 segmentbetween
L1 and CT was associated with a small rotation of the B20–B23 -turn and changes in main chain dihedral angles flanking B24. B, stick representation of
B-chain residues B20–B27 packed between CT and the L1 2 strand. Color code in insulin segment: carbon atoms (green), nitrogen (blue), and oxygen (red).
ResiduesB8–B19are shownas ablack ribbon, and theA-chain is shownas a yellow ribbon. Key contact surfacesofCTwithB24–B26arehighlighted inmagenta
and L1 with B24–B26 are highlighted in cyan. C, stereo view of the environment of TyrB26 within its binding site. Neighboring side chains in L1 and CT are as
labeled. This figure was adapted from Ref. 18 with permission of the authors.
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residues (Val715, Pro716, Arg717, and Pro718) that can only
accommodate trigonal -carbons (22). B25-related aromatic–
aromatic interactions are limited due to the peripheral location
of this residue (Fig. S11).
We chose to focus on position B26 because of its broad func-
tional tolerance of diverse substitutions (18). As illustrated
above (Fig. 8C), TyrB26 binds at the solvated periphery of the
IR interface. Indeed, substitution of small, polar, or charged
amino acids (such as Ala, Ser, or Glu) enhances receptor affin-
ity, but at the price of impaired self-assembly and decreased
thermodynamic stability with heightened susceptibility to
physical degradation (16). These findings highlighted the evo-
lutionary importance of the native dimer interface and dual role
of TyrB26. We thus hypothesized that an aromatic substitution
at the B26 positionmight enhance self-assembly without loss of
biological activity.
The classical structure of the insulin dimer motivated study
of successive aromatic–aromatic interactions as a physical
mechanism of stability (6, 64). The increased stability of ETF
aromatic–aromatic interactions involving Trp over those
involving Tyr contributes to the increased stability of the
TrpB26 hexamer. The larger size of the delocalized -orbital of
Trp in relationship to that of Tyr causes a stronger negative
charge to accumulate on the “face” of the indole ring. For this
reason, hydrogen atoms surrounding the aromatic rings of local
residues form stronger electrostatic interactions with the face
of the indole ring of Trp than with the phenol ring of Tyr (65,
66). Aromatic pairs involving Trp residues are less common
than those involving Tyr or Phe (1). However, the strength of
aromatic–aromatic interactions involving Trp is evidenced by
functional importance of Trp-based interactions; an example is
provided by a Trp–Tyr aromatic “lock” that stabilizes the active
conformation of the ghrelin receptor (67). Indeed, comparison
of electrostatic interactions of TrpB26 and TyrB26 within the
minimized model of the B16/B24/B26 aromatic network of
insulin revealed that interactions involving Trp were favored
over those involving Tyr across a broad variety of orientations
of the respective aromatic rings. Extension of the aromatic lock
metaphor (introduced by Holst et al. (67) to describe confor-
mational “trapping” in the GPCR structure) to the insulin hex-
amer highlights the kinetic effect of the B26 substitution on the
rate of hexamer disassembly (as probed by the Co2-EDTA
sequestration assay), which was more dramatic than effects on
equilibrium association (as probed by SEC). It would be of
future interest to measure activation energies for disassembly.
Insight into the structural origins of the prominent TrpB26-
associated kinetic lock may be provided by activated molecular
dynamics simulations of hexamer disassembly.
TrpB26 side chain exhibited an orientation similar to native Tyr
The TrpB26 side chain in the crystal structure of
[TrpB26,OrnB29]insulin displayed an orientation similar to that
of the native Tyr. A slight main chain shift in the B24–B28
-strand (0.2 (0.03) Å) was sufficient to enable native-like
packing of the larger indole ring against the core of a protomer
(Fig. S12). In both T and Rf subunits, the six-membered com-
ponent of the indole side chain was oriented toward IleA2,
ValA3, and ValB12. Based on the classical 3.5–6.5 inter-centroid
distance, residue TrpB26 (of the T protomer) showed potential
interactions with residues TyrD16 and PheD24. An interplanar
angle of 78 degrees between TrpB26 and TyrD16 was indicative
of classical aromatic–aromatic packing within proteins (2),
which generally range from50 to 90 degrees. TrpB26 and PheD24
displayed an interplanar angle of 36 degrees, however, this ori-
entation is less common. Similarly, in the Rf protomer, TrpD26
packed near TyrB16 and PheB24. The interplanar angle between
TrpD26 and TyrB16 was 62 degrees, whereas between TrpD26
andPheB24was 48 degrees. Previous studies have suggested that
Trp residues may form aromatic–aromatic interactions over
longer distances than those formed by Tyr–Phe pairs (68).
Thus, the two intra-chain aromatic pairs, TrpB26–PheB24 and
TrpD26–PheD24 (respectively, separated by 7.8 and 7.1 Å) may
interact more efficiently than the corresponding Tyr–Phe pairs
inWT insulin (ring geometries are summarized in Table S11, a
and b).
CHARMM calculations of aromatic–aromatic interactions
across the dimer interface of [TrpB26,OrnB29]insulin revealed
1.4 kcal/mol increased interaction energy. Residue by residue
analysis of each component of the aromatic network indicated
that the increased strength of interaction across the dimer
interfacewas the result of the interactions involvingTrpD26 (see
Table S9b). This result suggests that TyrB26 3 Trp may only
display stabilizing properties when in an R state protomer. If so,
the T6 hexamer formed by [TrpB26]insulin would be expected
to have dissociation kinetics similar toWT insulin, whereas the
corresponding R6 hexamer may be expected to have markedly
increased stability. The R3 T transition, which is rapid inWT
insulin on release of phenol, may represent the kinetic barrier
responsible for the meta-stable association state observed in
SEC experiments.
The packing of TrpB26/D26 within the respective cores of T-
and Rf crystallographic protomers is similar in each case to the
WT TyrB26/D26 and oriented such that the indole’s nonpolar
six-membered portion projects more deeply into a crevice
between A- and B-chains than does its proximal heterocycle.
Our 1HNMR studies of TrpB26 within an engineeredmonomer
(35) provided evidence that this overall conformation does not
require self-assembly. Analogous partial burial of TyrB26 and
TrpB26 in the respective protein structures would in itself be
expected to augment the variant’s stability due to enhanced
solvation free energy10 (69) (i.e. as predicted by water–octanol
transfer studies of free Tyr and Trp (69); Table S12). Guanidine
denaturation nonetheless, indicated that their stabilities are
indistinguishable.11
We speculate that the predicted residue-specific differences
in solvation free energy are attenuated by differences in protein
dynamics leading to EEC (70). Although the two B26 side
chains each exhibit upfield secondary 1H NMR shifts and anal-
ogous inter-residue NOEs, it is possible that the substitution is
associated with local or nonlocal differences in protein dynam-
10 The identification of a destabilizing Trp3 Tyr mutation in Escherichia coli
thioesterase-I demonstrated, in breach, the improved cavity-filling prop-
erties of Trp relative to Tyr (72).
11 That [TrpB26,OrnB29]insulin exhibited a greater exposure of nonpolar sur-
faces on denaturation in guanidine HCl than did [OrnB29]insulin was sug-
gested by a change inm values in two-state modeling (Table 2).
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ics. It would be of future interest to investigate dynamic features
by amide proton 1H–2H exchange and heteronuclear NMR
relaxation methods (70). Because TrpB26 promotes partial
dimerization of insulin lispro under NMR conditions (as indi-
cated by concentration-dependent 1H NMR resonance broad-
ening), such studies may require use of an alternative mono-
meric template.
Given the ubiquity of EEC as a confounding general aspect of
protein design (71), the profound effects of TrpB26 on the prop-
erties of the insulin hexamer seem all themore remarkable.We
envision that EEC is circumvented in this case by the rigidity of
the insulin hexamer (including the interlocked aromatic resi-
dues at its dimer interfaces) with efficient burial of theWT and
variant B26 side chains (72). With similar internal structures
and external solvation properties, the variant hexamer would
gain (relative toWT) two advantages from the Tyr3 Trp sub-
stitution: (i) greater B26-related solvation transfer free energy
(73) (Table S12) augmented by (ii) an uncompensated enthalpic
advantage arising from more favorable ETF aromatic interac-
tions as next discussed.
Molecularmechanics calculations rationalized physical and
pharmacologic properties
The structural rigidity of the R6 insulin hexamer (42, 74)
motivated local MM-based modeling to assess the interactions
contributing to the stability of the [TrpB26]insulin hexamers.
Analysis of insulin oligomers by Raman spectroscopy revealed
dampened conformational fluctuations of the R6 hexamer in
relationship to lower-order oligomers and T6 hexamers (72).
Moreover, the thermodynamic stability of the assembly was
evidenced by the lack of conformational changes visualized by
NMR spectroscopy over a temperature range of 10–80 °C (42).
The resistance of the R6 hexamer to structural perturbation has
also been shown in the context of mutant insulin analogs:
native-like X-ray crystal structures have been reported of R6
containing a broad range of substitutions (Table S13) (17, 75,
76). Even substitutions thatwere shown to destabilize the dimer
interface of insulin, such as the substitution of PheB24 by the
nonaromatic cyclohexylalanine, were shown to have little
impact on the global structure of the R6 hexamer. For this rea-
son, the TyrB263 Trp substitution was expected to affect only
the local structure of the insulin hexamer. Thus, the effects of
the mutation were amenable to initial analysis in simplified
(eight-ring) models of the dimer interface of insulin.
Energy minimization of a local model of [TrpB26]insulin (i.e.
as substituted into a WT insulin dimer extracted from a repre-
sentative crystal structure of a T3Rf3 zinc hexamer) yielded a
native-like framework with enhanced nearest-neighbor B26-
related aromatic–aromatic interactions. The partial-charge
(monopole) model of the aromatic rings in the CHARMM
empirical energy function, parametrized in accordance with ab
initio simulations (77), predicted an increase of 0.8 kcal/mol.
Although this calculation could in principle have been con-
founded by transmitted conformational perturbations and did
not consider potential changes in conformational entropy or
solvation, its conservative features were verified by X-ray crys-
tallography. That the structure of [TrpB26,OrnB29]insulin is
essentially identical to WT suggests that local properties of
TrpB26 directly underlie the observed increase in hexamer sta-
bility and lifetime.
The general asymmetry of the variant TRf dimer in the crys-
tallographic hexamer was associated with differences in the
details of corresponding aromatic–aromatic interactions
across the dimer interface. Although CHARMM calculations
predicted an increase of a 1.4 kcal/mol in interaction energies
(0.7 kcal/mol per protomer) in accordancewith our initialmod-
eling, residue by residue decomposition ascribed this increase
primarily to TrpD26 (in the Rf protomer) and not to TrpB26 (in
the T protomer). It is formally possible that TrpB26 is only sta-
bilizing in an R state, but additional studies would be required
to resolve this issue. Our cobalt-EDTA sequestration studies
focused on the R6 state as the preferred storage vehicle in a
pharmaceutical formulation. On SQ injection, rapid diffusion
of phenolic ligands from the depot leads to a TR transition.
That TrpB26 was found to delay subsequent absorption into the
bloodstream suggests that this substitution also enhances the
kinetic stability and lifetime of the T6 hexamer.
A seeming paradox is posed by the evolutionary exclusion of
Trp at position B28 of vertebrate insulins despite the evident
compatibility of this aromatic side chain with native structure
and function. We speculate that this exclusion reflects
the biological importance of the rapid disassembly of zinc
insulin hexamers on their secretion by pancreatic -cells.
Whereas the enhanced thermodynamic and kinetic stabili-
ties of [TrpB26]insulin hexamers would seem favorable for stor-
agewithin secretory granules (as within pharmaceutical formu-
lations) (8), delayed disassembly of the variant hexamers in the
portal circulation would be predicted to reduce the hormone’s
bioavailability on first pass through the liver, as insulin dimers
and hexamers cannot bind to the IR (78). Such delayed disas-
sembly might also decrease the delivery of free zinc ions to the
liver, recently predicted to constitute a regulatory signal in its
own right (for review, see Ref. 79).
The resulting impairment in hormonal regulation of hepatic
metabolism (and accompanying systemic hyperinsulinemia
(80)) could in principle have imposed a selective disadvantage
in the course of vertebrate evolution. Although to our knowl-
edge, such a kinetics-based mechanism has not been observed
in vivo, the converse, abnormally rapid clearance of insulin, has
been found on release from zinc-deficient secretory granules;
presumably zinc-free insulin oligomers more rapidly dissociate
on dilution in the portal circulation and so are more efficiently
cleared than WT zinc insulin hexamers (81). Similarly, the
exclusion of Trp at position B26 of vertebrate IGFs may reflect
a disadvantageous competition between self-assembly and
binding to IGF-binding proteins, which are critical to the inte-
grated physiology of IGF function (for review, see Ref. 82). Such
functional complexity may impose hidden constraints on the
evolution (and so divergence) of protein sequences. The con-
served “aromatic triplet” of vertebrate insulins and IGFs pro-
vides a natural laboratory to uncover such evolutionary con-
straints (45). These considerations further suggest that
structural features of a protein pertinent to its endogenous
function may in general be distinct from those biophysical
properties that may be re-engineered to optimize molecular
pharmacology.
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Comparison of [TrpB26]insulin and a corresponding iodo-Tyr
analog
Design of [TrpB26]insulin was in part motivated by prior
studies of an analog containing 3-iodo-Tyr at the B26 (17, 23,
83). The latter analog (“3I-Y-insulin”) exhibited a variety of
favorable properties: increased affinity for the IR (83), increased
thermodynamic stability, and augmented resistance to fibrilla-
tion (17). Moreover, when formulated as an R6 hexamer, this
analog exhibited a decreased dissociation rate (17). Because
modified amino acids raise the cost and complexity of protein
manufacture, wewonderedwhether a natural amino acidmight
mimic, at least in part, the structure of 3I-Y-insulin and so
confer favorable pharmacologic properties with conven-
tional manufacturing.
This translational goal motivated our initial MM-based local
modeling of [TrpB26]insulin. Analysis of the crystal structure of
3I-Y-insulin, determined as an R6 zinc hexamer (23), revealed
that the large, nonpolar iodo-substituent packed within the
core of the insulin protomer with preservation of a native-like
dimer interface. Molecular dynamics simulations, undertaken
with a multipolar electrostatic model of the modified aromatic
ring (23), rationalized this conformation: the iodine atom effi-
ciently filled a cryptic packing defect inWT insulin, lined by the
conserved side chains of IleA2, ValA3, andTyrA19. The enhanced
packing efficiency of the modified insulin and novel network
of halogen-specific electrostatic interactions (“weakly polar”
interactions (1)) appear to underlie the analog’s increased ther-
modynamic stability and resistance to fibrillation.Whereas the
standard partial-charge model of aromatic systems failed to
account for the conformation of iodo-Tyr observed in the crys-
tal structure, a multipolar electrostatic model rationalized ther-
modynamic stabilization of the dimer interface by this halogen
“anchor” (23). Subtle changes in the geometry of aromatic–
aromatic interactions were observed both in the simulations
and in the crystal structure. Although activated MD simula-
tions were not undertaken to probe the process of dimer disso-
ciation, we presume that the above mechanisms of ground-
state stabilization, enhanced core packing efficiency, and a
halogen-specific weakly polar network, also underlie the
increased barrier to dissociation as indicated by the prolonged
lifetime of the variant R6 hexamer (23).
Although the profound QM effects of halo-aromatic substi-
tutions, including weakly polar interactions and “halogen
bonding” (84), cannot be recapitulated by natural amino acids,
it seemed possible that enhanced core packing efficiency might
be achieved by analogy to 3I-Y-insulin. Indeed, the steric profile
of the asymmetric indole side chain of Trp is similar in size to
3-iodo-Tyr. Accordingly, we imagined that the offset six-mem-
bered portion of the bicyclic indole ring might pack within the
core of insulin in a manner similar to the iodine atom. In this
intuitive picture the extended -system of TrpB26 was envi-
sioned to interact with neighboring residues to recapitulate, at
least in part, the favorable electrostatic properties of iodo-
TyrB26 (23, 37).
The above line of reasoning led to the present set of stud-
ies. In accordance with our original intuition and local MM-
based modeling, the crystal structures of 3I-Y-insulin and
[TrpB26,OrnB29]insulin exhibited similar features. Neverthe-
less, salient differences between the quantum-chemical prop-
erties of iodo-Tyr and Trpmight make the similar structures of
these B26 analogs a fortuitous outcomeof distinctmechanisms.
Whereas effects of 3-iodo-Tyr on aromatic–aromatic interac-
tions at the insulin dimer interface are subtle, presumably
reflecting indirect inductive effects of iodo-substitutent (23),
substitution of Tyr by Trp introduces a larger aromatic surface
at this interface. It is possible that this feature underlies the
more marked impact of TrpB26 on insulin oligomerization rel-
ative to 3-iodo-Tyr.
Aromatic–aromatic interactions exemplify limitations of
classical models
The quantum origins of aromatic–aromatic interactions are
complex, and so classical electrostatic models (such as partial-
charge model of Tyr in the standard CHARMM empirical
energy function) can be incomplete (85). Although QM calcu-
lationsmore fully capture this complexity, a tradeoff is encoun-
tered between rigor and computational feasibility, especially in
complex systems such as proteins (86), but even in ab initio
simulations of benzene–benzene interactions (46). Standard
MMandMDmethods thus employ parametrized force fields to
approximate quantum-chemical interactions (21). Although
parameters (e.g. partial charges assigned to an aromatic ring)
have been chosen to provide reasonable protein models, such
use of “monopolar” electrostatics neglects the polarizability of
aromatic systems and so omits dispersion forces (87). Parame-
trized classical models may thus mischaracterize the strength
or directionality of intermolecular interactions, particularly
those involving more than one aromatic group or an aromatic
group and a chargedmoiety. Although the pioneering studies of
Burley and Petsko (88) suggested that the partial-charge model
of aromatic rings in proteins was sufficient for characterizing
aromatic–aromatic interactions, more recent work has high-
lighted its limitations with respect to delineating underlying
physical mechanisms (85, 89). The limits of parametrized clas-
sical force fields are of particular importancewhen applications
are sought in nonstandard systems (such as unnatural protein
mutagenesis (90)) for which the parameters were not intended.
Examples are provided by halogen-modified aromatic systems
(widely employed inmedicinal chemistry) (91), which are asso-
ciated with marked changes in quantum-chemical properties
(92). Formal QM/MMsimulations of proteinsmay nonetheless
be circumvented through force fields incorporating multipolar
electrostatic models of aromatic–aromatic networks (85).
The correspondence between our initial local MM-based
modeling and our experimental findings, however striking,may
be coincidental (93): rigorous elucidation of the physics of the
variant aromatic cluster at insulin’s dimer interfacemay require
application of free-energy MD-based simulations with explicit
inclusion of water molecules (“molecular alchemy” (94)). This
approach may also provide insights into whether or how EEC
may be circumvented. Nevertheless, standardMMcalculations
can guide initial biochemical analysis of protein structure as a
guide for protein engineering. In the present study such initial
modeling reinforced our structural intuition by highlighting
the plausibility that substitution of TyrB26 by Trp might pre-
Stabilization of insulin hexamer
J. Biol. Chem. (2018) 293(28) 10895–10910 10905
serve a native-like interface and in fact enhance its weakly polar
properties. Because the rigid hexameric framework provided a
favorable context for local modeling of amino acid substitu-
tions at subunit interfaces and yet it is the monomer that func-
tions as a hormone in the bloodstream, it would be of future
interest to apply more sophisticated computational techniques
to simulate the structure and dynamics of [TrpB26]insulin as a
monomer in solution. Such predictions may in principle be
tested through biophysical studies of an engineered insulin
monomer containing TrpB26. Although this substitution is favor-
able in the context of the hexamer (and so of potential pharmaco-
logic benefit), design of a monomeric NMR model will need to
overcome the confounding effects of TrpB26, as defined in this
experimental context, to promote self-association.
Concluding remarks
To our knowledge, this study represents the first exploitation
of aromatic–aromatic interactions to enhance the biophysical
properties of a therapeutic protein (95). Our approach may be
broadly applicable in protein engineering (as ETF interactions
are ubiquitous) and generalizable to nonstandard aromatic
moieties. The latter would be likely to require QM/MMmeth-
ods rather than classical force fields parametrized with partial
charges (90). Overall effects of such substitutions on protein
stability and self-assembly will require an integrated analysis of
solvation free energies (86), changes in protein dynamics (96),
and potential EEC (97). Three- and four-dimensional hetero-
nuclear NMR experiments would be expected to provide high-
er-resolution information regarding the local and nonlocal
interactions of the optimized aromatic system. In the present
application, analyses of 15N relaxation and 1H–2H amide–
proton exchange are expected to improve understanding of the
molecular dynamics of the TrpB26-modified aromatic cluster
and so provide a more rigorous biophysical context for its
enhanced self-association properties (70, 96).
The present application to insulin demonstrates a direct rela-
tionship between stabilization of the insulin hexamer and pro-
longed activity of a basal analog. Continuous and flat 24-h insu-
lin activity (“peakless” basal formulations) is of clinical interest
in the treatment of Type 1 and Type 2 diabetes mellitus to
reduce the risk of hypoglycemia (especially at night) at a given
level of glycemic control (98). Because this mechanism is unre-
lated to present strategies to achieve protracted action, we
envision that TrpB26-related enhancement of dimer-specific
aromatic–aromatic interactions could favorably be introduced
into current basal insulin formulations. In the future a combi-
nation of orthogonal molecular strategies might enable devel-
opment of a once-a-week basal insulin therapy analogous to
that of GLP-1 agonists (99). Optimization of weakly polar inter-
actionsmay thus assume a central place in the toolkit of molec-
ular pharmacology.
Experimental procedures
Materials
Insulin was purchased from BioDel (Danbury, CT). Insulin
glarginewas obtained fromLantus (Sanofi-Aventis, Paris, FR).
Reagents for peptide synthesis were as described (100).
Preparation of insulin analogs
Variant insulins were prepared by semisynthesis (101). In
brief, synthetic peptides were coupled to a tryptic fragment of
insulin (des-octapeptide [B23-B30]insulin) in aqueous/organic
solvent using trypsin as a catalyst. Following RP-HPLC purifi-
cation, predictedmolecularmasses were confirmed byMS (33).
Hexamer disassembly assays
Disassembly of phenol-stabilized (R6) Co2-substituted
insulin hexamers was monitored as described (102). In brief,
WT insulin or variants were made 0.6 mM in buffer containing
50mMTris-HCl (pH7.4), 50mMphenol, and 0.2mMCoCl2 (18)
and incubated overnight at room temperature to attain confor-
mational equilibrium. Spectra (400–750 nm) were obtained to
monitor tetrahedral Co2 coordination (27) through its signa-
ture absorption band at 574 nm (27). Co2 sequestration was
initiated by addition of EDTA to a concentration of 2 mM. Dis-
sociation was probed via attenuation of a 574-nm band (27);
data were fit to a monoexponential decay equation (29).
Protein crystallography
Crystals were obtained by hanging drop vapor diffusion at
room temperature in the presence of a 1:1.7 ratio of Zn2 to
protein monomer and a 3.5:1 ratio of phenol to protein mono-
mer in Tris-HCl. Diffraction was observed using synchrotron
radiation at a wavelength of 0.9795 Å at the Stanford Synchro-
tron Radiation Light Source (beamline BL7-1); crystals were
flash frozen to 100 K. Structure determination was carried out
using molecular replacement using CCP4 (103) and Phenix
structure-determination suites (104). The resulting structure
was validated using a PDB Redo server (105). The lattice con-
tained one TRf dimer per asymmetric unit. The main chain
conformations of the 97 residues in the refinedmodel of theTRf
dimer in the asymmetric unit (excluding 2 Thr, 1 Orn, and 1
Phe residues) each resided in a most favored Ramachandran
region.
Receptor-binding assays
Analog affinities for detergent-solubilized IR-B holoreceptor
were measured by a competitive-displacement assay (18). Suc-
cessive dilutions ofWT insulin or analogs were incubated over-
night with wheat germ agglutinin-SPA beads (PerkinElmer Life
Sciences), receptor, and radiolabeled tracer before counting
(18). To obtain dissociation constants, competitive binding
data were analyzed by nonlinear regression by the method of
Wang (106).
Rat studies
Male Lewis rats (mean mass300 g) were rendered diabetic
by streptozotocin. Effects of insulin analogs formulated in
Lilly buffer (18) on blood glucose concentration following
SQ injection were assessed in relationship to WT or
[OrnB29]insulin (18). [OrnB29]Insulin and [TrpB26,OrnB29]
insulin were made in the above buffer. GlyA21, OrnB29,
OrnB31, OrnB32, TrpB26 and GlyA21, OrnB29, OrnB31, and
OrnB32 were dissolved in diluted HCl (pH 4) containingmeta-
cresol, glycerol, and a 1:2 ratio of ZnCl2:insulin monomer. Rats
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were injected SQ with 3.44 nmol of insulin or insulin analogs
(12–13.7 nmol).
Animals used in this studywere housed in theAssociation for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC)-accredited facilities of Case Western Reserve Uni-
versity (CWRU) School of Medicine. All procedures were
approved by the Institutional Animal Care and Use Committee
(IACUC)Office at CWRU,which provided StandardOperating
Procedures and reference materials for animal use (in accord-
ance with the NIH Guide for the Care and Use of Laboratory
Animals). The animal health program for all laboratory animals
was directed by the CWRU Animal Resource Center. Animal
care and use was further monitored for Training and Compli-
ance issues by Veterinary Services.
Size exclusion chromatography
Analogs weremade 0.6mM in 10mMTris-HCl (pH 7.4), 1.6%
glycerol (v/v), 0.3 mM ZnCl2, and 7 mM phenol (33). Insulin
samples (20 l) were loaded on an Enrich SEC70 column
(10 300 mm with fractionation range 3–70 kDa); the mobile
phase consisted of 10mMTris-HCl (pH 7.4), 140mMNaCl, and
0.02% sodium azide. Elution times were monitored by absor-
bance at 280 nm. Molecular masses and void volume (V0) were
inferred in reference to standard proteins (18).
Spectroscopy
CD spectra were acquired in 10 mM potassium phosphate
(pH 7.4) and 50 mM KCl (33). Free energies of unfolding (Gu)
were inferred at 25 °C from two-statemodeling of protein dena-
turation by guanidine HCl (33, 34). 1H NMR spectra were
acquired at 700MHz at pH 8.0 or pD 7.6 (direct meter reading)
at 37 °C (36). Chemical shifts of aromatic protons in residues
B24–B24 (Phe-Phe-Tyr or Phe-Phe-Trp) were evaluated in
relationship to corresponding chemical shifts in respective
octapeptides B23–B30, presumed to represent random-coil
shifts.
Molecularmechanics calculations
Calculations were performed using CHARMM (kindly pro-
vided by Prof. M. Karplus). Its standard empirical energy func-
tion was employed (in whose development aromatic rings were
parametrized by partial atomic charges in accordance with ab
initioQM simulations (21)). RepresentativeWT insulin dimers
were obtained from PDB entries 4INS, 1ZNJ, and 1TRZ. These
structures and corresponding TrpB26 homology models were
subjected to local energy minimization (100 steps of steepest
descent followed by Adopted Basis Newton-Raphson with gra-
dient tolerance tolg 0.0008/10,000 steps). Minimizations were
halted either at 1,000 steps or when the above tolerance was
reached. Changes in conformation were allowed only to eight
side chains (TyrB16, PheB24, PheB25, TyrB26 (or TrpB26), and
their dimer-related mates; the remaining atoms in the respec-
tive dimers were fixed. Total interaction energies and respec-
tive electrostatic components were obtained between the side
chain of residue B26 and the neighboring three aromatic side
chains (PheB24 and dimer-related TyrD16 and PheD24). Follow-
ing this survey of crystallographic dimers, such energies were
further evaluated in a simplified molecular model that con-
tained only the side chains of residues TyrB26 (or TrpB26) and
the sameneighboring three aromatic residues as extracted from
PDB entry 4INS; this yielded the electrostatic interaction
energy map shown in Fig. 2, in which B26 1 and 2 dihedral
angleswere systematically variedwithout energyminimization.
Quantummechanics calculations
Electron density and molecular electrostatic potential of Tyr
and Trp side chains were calculated with B3LYP and 6-31G(d)
basis sets using Gaussian utility Cubegen in Gaussian09 (77).
The isosurfacemapwasgeneratedusing Jmol (107).Abinitioener-
gies of interaction between pairs of isolated aromatic rings were
determined by calculating interaction energies using the MP2
method with the aug-cc-pVDZ basis set in Gaussian 09 (77).
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